Zentalis Pharmaceuticals Reports Q2 2026 Financial Results

What Happened

• On August 6, 2026, Zentalis Pharmaceuticals, Inc. announced its financial results for the quarter ended June 30, 2026 via a press release furnished as Exhibit 99.1 to the Form 8-K. The filing also furnished a corporate presentation (Exhibit 99.2) that company spokespersons will use in investor and analyst meetings beginning August 6, 2026.
• The Form 8-K states the press release and presentation are furnished (not filed) and incorporated by reference into the current report; the full financial details and business updates are contained in those exhibits.

Key Details

• Date of announcement: August 6, 2026.
• Reporting period: Quarter ended June 30, 2026.
• Exhibits furnished: Press release (Exhibit 99.1) and Corporate Presentation (Exhibit 99.2).
• Regulation FD note: Management will present the furnished corporate presentation at conferences and investor/analyst meetings starting August 6, 2026.

Why It Matters

• This 8-K makes Zentalis’ quarterly results and investor presentation publicly available—materials investors should review to assess recent earnings, revenue, cash position, and any business or pipeline updates disclosed in the exhibits.
• Because the materials are furnished (not filed), they are provided for investor information but are not subject to certain Exchange Act liabilities; investors should read the actual press release and presentation for the specific financial figures and management commentary.